»ùÒòµãÍ»±äÔØÌå¹¹½¨
ЧÀÍÏêÇé
| ½»¸¶±ê×¼ | 1.ÖÊÁ£Í¼Æ×2.ÖÊÁ£²âÐòЧ¹û3.ÖÊÁ£²Ù×÷˵Ã÷4.ÖÊÁ££¨pegRNA+sgRNAÈý×飩£¬£¬£¬¸¨ÖúÖÊÁ££¨»ìÏý¹Ü£© |
|---|---|
| ÖÜÆÚ/¼ÛÇ® |
¿ìÖÁ2ÖÜ£¬£¬£¬6880ÔªÆð |
ЧÀÍÓÅÊÆ
¸ßЧµÄ±à¼ÏµÍ³
¸ßЧpegRNAÉèÅÌË㷨ϵͳ
ÔöÇ¿Ð͵ÄCas9n-RT±à¼Ã¸ÏµÍ³£º
רҵµÄ¼¼ÊõÖ§³ÖÍŶÓ
ÖÊÁ£Í¼Æ×
Advantage and Characteristic
Optimazied Strategy
Optimazied Strategy
Optimazied Strategy
Optimazied Strategy
²Î¿¼ÎÄÏ×
HEK293Tϸ°ûÖÐʵÏÖCFTR»ùÒòµÄµãÍ»±ä
ÄÒÐÔÏËά»¯£¨Cystic Fibrosis, CF£©ÊÇÒ»ÖÖÓÉ¿çĤ´«µ¼µ÷ÀíÂѰף¨CFTR£©Ë«µÈλ»ùÒò¹¦Ð§Ëðʧͻ±äÒýÆðµÄ³£¼ûµÄÒÅ´«ÐÔÖÂÃü¼²²¡¡£¡£¡£¡£ÒÑÍùÒÑÓжàÖÖCFTRµ÷Àí¼ÁÁÆ·¨»ñµÃÅú×¼£¬£¬£¬µ«ÕâЩ¸ßЧµ÷Àí¼Á£¨HEMTs£©Ö»ÊÊÓÃÓÚÖÁÉÙÓÐÒ»¸öF508delµÈλ»ùÒò»òÆäËûÏìÓ¦ÐÔCFTRÍ»±äµÄ»¼Õߣ¬£¬£¬ÎÞ·¨ÎªÐí¶à£¨³¬£©ÓÐÊýµÄCFTRÍ»±ä»¼ÕßÌṩÖÎÁÆÒªÁì¡£¡£¡£¡£Ëæ×Å¿ÆÑ§Ñо¿Éú³¤£¬£¬£¬ÈËÃÇ·¢Ã÷»ùÒòÖÎÁÆÄÜΪÕâЩͻ±äÌṩÁËеÄÖÎÁÆÊ±»ú¡£¡£¡£¡£ÌØÊâÊÇ×î½ü¿ª·¢µÄ»ùÓÚCRISPRµÄϵͳ——prime editing£¨PE£©£¬£¬£¬ÎªÖÎÁÆÒÅ´«ÐÔ¼²²¡¿ª·¢ÁËеÄʱ´ú¡£¡£¡£¡£Prime editingÄܹ»ÔÚ»¼ÕßµÄȾɫÌåÉÏÔλ“ÖØÐ´”ºÍ¾ÀÕýÍ»±ä£¬£¬£¬ÌṩÁËÖÎÁƵ¥»ùÒò¼²²¡ÈçCFµÄÐÂʱ»ú¡£¡£¡£¡£
ÔÚÕâÆªÎÄÕÂÖУ¬£¬£¬Ñо¿Ö°Ô±Ê¹ÓÃCRISPR-Cas9¼¼ÊõÉè¼ÆÁËÕë¶ÔCFTR»ùÒòÖÐL227RºÍN1303KÁ½ÖÖÍ»±äµÄprime editing²ßÂÔ£¬£¬£¬²¢ÔÚHEK293Tϸ°ûÖй¹½¨ÁËÎȹ̱í´ï3HA-L227R-CFTRºÍ3HA-N1303K-CFTRµÄϸ°ûÄ£×ÓÀ´ÆÀ¹Àprime editingµÄЧ¹û¡£¡£¡£¡£ÔÚ¿ª·¢µÄDETECTOR»úеѧϰËã·¨°ü¹ÜЧÂʺÍ׼ȷÂʵÄÇéÐÎÏ£¬£¬£¬Ñо¿Ö°Ô±½øÒ»²½¾ÙÐлùÒòºÍ¹¦Ð§Ð£ÕýµÄÆÀ¹À£¬£¬£¬Ð§¹ûÏÔʾ±à¼Ð§ÂÊ×î¸ß¿É´ï25%£¬£¬£¬¾ÀÕýºóµÄCFTRÂѰ×ÔÚÌÇ»ù»¯¡¢¶¨Î»ºÍÀë×ÓͨµÀ¹¦Ð§·½Ãæ»ñµÃÁËÏÔÖø»Ö¸´¡£¡£¡£¡£ÕâЩЧ¹ûÒ²ÔÚÔ´úϸ°ûÄ£×ÓÊÔÑéÖлñµÃÑéÖ¤¡£¡£¡£¡£±ðµÄ£¬£¬£¬Ê¹ÓÃÈ«»ùÒò×éÆÀ¹ÀÆÊÎö£¬£¬£¬Ñо¿Ô±ÃDz¢Î´·¢Ã÷ÏÔÖøµÄÍѰбà¼ÊÂÎñ£¬£¬£¬Ö¤ÊµÎúprime editingµÄ¸ß±£Õæ¶È£¬£¬£¬²¢ÇÒ¸ÃÑо¿µÄÁÙ´²Ïà¹ØÐÔÓëÇå¾²ÐÔÆÀ¹ÀÒ²»ñµÃͨ¹ý¡£¡£¡£¡£×ܵÄÀ´Ëµ£¬£¬£¬ÕâÏîÑо¿Õ¹Ê¾ÁËprime editing¼¼ÊõÔÚ¾ÀÕýCFTR»ùÒòÍ»±äºÍ»Ö¸´CFTRÂѰ׹¦Ð§·½ÃæµÄDZÁ¦£¬£¬£¬ÎªÄÒÐÔÏËά»¯µÄÖÎÁÆÌṩÁËеÄ˼Ð÷ºÍÒªÁì¡£¡£¡£¡£
¾«Ñ¡¿Í»§ÎÄÕÂ
Deep whole-genome analysis of 494 hepatocellular carcinomas
È«ÇòÁè¼ÝÒ»°ëµÄ¸Îϸ°û°©£¨HCC£©²¡Àý±¬·¢ÔÚÖйú£¬£¬£¬µ«ÏÖÔÚÕë¶ÔÖйúÈËȺÖÐÒÒÐ͸ÎÑײ¡¶¾£¨HBV£©Ïà¹ØHCCµÄÈ«»ùÒò×éÆÊÎöÑо¿ºÜÊÇÓÐÏÞ¡£¡£¡£¡£ÎªÁËÍ»ÆÆÕâÖÖÏÞÖÆ£¬£¬£¬Ñо¿Ö°Ô±Æô¶¯ÁË“Öйú¸Î°©Í¼Æ×ÏîÄ¿”£¨CLCA£©£¬£¬£¬Ö¼ÔÚ¶ÔÖйúÈËȺÖеÄHCC¾ÙÐдó¹æÄ£µÄÈ«»ùÒò×éÆÊÎöÒÔÃ÷È·ÆäÆæÒìµÄ·¢²¡»úÖÆºÍ½ø»¯Àú³Ì¡£¡£¡£¡£¸ÃÏîÄ¿¶Ô494ÀýHCCÖ×ÁöÑù±¾¾ÙÐÐÁËÉî¶ÈÈ«»ùÒò×é²âÐò£¨Æ½¾ù²âÐòÉî¶ÈΪ120×£©£¬£¬£¬²¢ÆÊÎöÁËÆ¥ÅäµÄ±ÈÕÕѪҺÑù±¾£¬£¬£¬Õ¹ÏÖÁËHBVÏà¹ØHCCµÄÏêϸ»ùÒò×éÌØÕ÷¡£¡£¡£¡£Ñо¿·¢Ã÷£¬£¬£¬³ýÁËÒÑÖªµÄ±àÂëÇøÇý¶¯»ùÒò£¨ÈçTP53ºÍCTNNB1£©Í⣬£¬£¬»¹±£´æ6¸öеıàÂëÇøÇý¶¯»ùÒò£¨°üÀ¨FGA£©ºÍ31¸ö·Ç±àÂëÇøÇý¶¯»ùÒò¡£¡£¡£¡£±ðµÄ£¬£¬£¬Ñо¿»¹Õ¹ÏÖ5ÖÖеÄÍ»±äÌØÕ÷£¨°üÀ¨SBS_H8£©£¬£¬£¬ÒÔ¼°HBVÕûºÏÐγÉϸ°ûÍâ»·×´DNA£¨ecDNA£©µÄÕ÷Ï󣬣¬£¬ÕâЩecDNA¿Éµ¼Ö°©»ùÒòÀ©ÔöºÍ±í´ïÔöÌí¡£¡£¡£¡£Í¨¹ý¹¦Ð§Ñé֤ʵÑ飬£¬£¬Ñо¿Ö°Ô±Ö¤ÊµÁËFGA¡¢PPP1R12BºÍKCNJ12µÈ»ùÒòµÄÍ»±äÄܹ»ÏÔÖøÓ°ÏìHCCϸ°ûµÄÔöÖ³¡¢Ç¨áãºÍÇÖÏ®ÄÜÁ¦¡£¡£¡£¡£ÕâÏîÑо¿Ð§¹û²»µ«¸»ºñÁËÈËÃǶÔHCC»ùÒò×éѧµÄÃ÷È·£¬£¬£¬Ò²ÎªHCCµÄÕï¶ÏºÍÖÎÁÆÌṩÁËеÄDZÔڰе㡣¡£¡£¡£

ºòÑ¡Çý¶¯Òò×Ӹſö
Targeted Macrophage CRISPR-Cas13 mRNA Editing in Immunotherapy for Tendon Injury
¼¡ëìËðÉ˼±ÐÔÑ×Ö¢ÆÚÖУ¬£¬£¬¾ÞÊÉϸ°ûÌ«¹ý¼¤»î»áµ¼Ö±àÂë¹ÇÇÅÂѰ×OPNµÄSPP1¹ý±í´ï£¬£¬£¬Ó°Ïì×éÖ¯ÔÙÉú¡£¡£¡£¡£CRISPR-Cas13ÓÉÓÚ¾ßÓÐRNA±à¼ºÍ¿ìËÙ½µ½âµÄÄÜÁ¦£¬£¬£¬ÔÚ×éÖ¯ÐÞ¸´·½Ãæ¾ßÓÐÖØ´óDZÁ¦£¬£¬£¬µ«È±·¦ºÏÊÊÓÐÓõĵÝËÍÒªÁì¡£¡£¡£¡£¶Ô´Ë£¬£¬£¬Ñо¿Ö°Ô±ÏµÍ³É¸Ñ¡ÁËÕë¶Ô¾ÞÊÉϸ°ûµÄÑôÀë×Ó¾ÛºÏÎ£¬£¬¿ª·¢ÁËÒ»ÖÖÄܹ»¸ßЧµÝËÍCas13ºËÌǺËÂѰ׸´ºÏÎCas13 RNP£©½øÈë¾ÞÊÉϸ°ûµÄÄÉÃ×´ØÔØÌå¡£¡£¡£¡£Í¨¹ý·´Ó¦ÐÔÑõÖÖ£¨ROS£©ÏìÓ¦ÐÔÊÍ·Å»úÖÆ£¬£¬£¬¸ÃϵͳÄܹ»ÔÚ¼¡ëìËðÉ˵ļ±ÐÔÑ×֢΢ÇéÐÎÖÐÌØÒìÐÔÒÖÖÆ¾ÞÊÉϸ°ûÖÐSPP1µÄ¹ý±í´ï¡£¡£¡£¡£ÊµÑéЧ¹ûÅú×¢£¬£¬£¬ÕâÖÖ°ÐÏò²ßÂÔÏÔÖøïÔÌÁËËðÉËÓÕµ¼µÄSPP1±¬·¢¾ÞÊÉϸ°ûµÄ·ºÆð£¬£¬£¬½µµÍÁ˳ÉÏËάϸ°ûµÄ¼¤»î£¬£¬£¬²¢¼õÇáÁ˼¡ëìÖÜΧµÄÕ³Á¬Ðγɡ£¡£¡£¡£±ðµÄ£¬£¬£¬¸ÃÑо¿»¹Õ¹ÏÖÁËSPP1ͨ¹ýCD44/AKTÐźÅͨ·Ôö½ø³ÉÏËάϸ°û»î»¯ºÍǨáãµÄ»úÖÆ£¬£¬£¬²¢Í¨¹ýÒÖÖÆÕâһͨ·ÓÐÓûº½âÁ˼¡ëìËðÉ˺óµÄÕ³Á¬ÎÊÌâ¡£¡£¡£¡£

ÓÃÓÚPAÖÎÁƵľÞÊÉϸ°ûÃâÒß΢ÇéÐ줻îmRNA±à¼²ßÂÔµÄʾÒâͼ
Electrical stimulation of piezoelectric BaTiO3 coated Ti6Al4V scaffolds promotes anti-inflammatory polarization of macrophage and bone repair via MAPK/JNK inhibition and OXPHOS activation
¼¹ËèËðÉË£¨SCI£©ÊÇÒ»ÖÖµ¼Ö¸ÐÊÜ×ÔÖ÷Éñ¾ºÍÔ˶¯¹¦Ð§µÄÓÀÊÀÐÔË𺦵ÄÑÏÖØÖ²ÐÐÔ¼²²¡¡£¡£¡£¡£¸Éϸ°ûÁÆ·¨£¬£¬£¬ÓÈÆäÊǼä³äÖʸÉϸ°û£¨MSCs£©£¬£¬£¬ÔÚSCIÖÎÁÆÖÐÕ¹ÏÖ³öÖØ´óDZÁ¦µ«ÆäÔÙÉúÄÜÁ¦ÓÐÏÞ£¬£¬£¬ÕâÏÞÖÆÁËÆäÔÚ×éÖ¯ÔÙÉúÖеÄÓ¦Óᣡ£¡£¡£Ñо¿ÍŶÓÊӲ쵽ABPCsÑÜÉúµÄEVs£¨EVsABPC£©¿ÉÄÜЯ´øÔö½ø×éÖ¯ÔÙÉúµÄÉúÎï»îÐÔÐźţ¬£¬£¬Òò´ËËûÃÇ´Ó¹½ÇÑ¿»ù×æÏ¸°û£¨ABPCs£©ÖÐÌáÈ¡²¢ÐÞÊÎÁËϸ°ûÍâÄÒÅÝ£¨EVsABPC£©£¬£¬£¬²¢½«ÆäÓ¦ÓÃÓÚ¼¹ËèËðÉË£¨SCI£©µÄÖÎÁÆÑо¿¡£¡£¡£¡£Ñо¿Ö°Ô±·¢Ã÷EVsABPCÄܹ»ÏÔÖøÔöÇ¿Éñ¾¸Éϸ°û£¨NSCs£©µÄÔöÖ³£¬£¬£¬Ôö½øÖáÍ»Éú³¤£¬£¬£¬ïÔÌÉñ¾ÔªµòÍö£¬£¬£¬²¢Í¨¹ýµ÷ÀíÑ×Ö¢·´Ó¦½«¾ÞÊÉϸ°û´Ó´ÙÑ×µÄM1Ðͼ«»¯Îª¿¹Ñ×µÄM2ÐÍ¡£¡£¡£¡£±ðµÄ£¬£¬£¬¾Óɹ¤³Ì»¯Ë¢ÐµÄEVsABPC£¨Í¨¹ý¼¤»îϸ°û´©Í¸ëÄÐÞÊΣ©Äܹ»¸üÓÐÓõذÐÏòSCIËðÉ˲¿Î»£¬£¬£¬ÏÔÖø¸ÄÉÆÉñ¾ÔÙÉúºÍÔ˶¯¹¦Ð§»Ö¸´¡£¡£¡£¡£ÕâЩЧ¹ûÅú×¢£¬£¬£¬EVsABPCÊÇÒ»ÖÖ¼«¾ßDZÁ¦µÄSCIÖÎÁƺòÑ¡¼Æ»®¡£¡£¡£¡£

ͼ½âÕªÒª
Generation of recombinant antibodies by mammalian expression system for detecting S-metolachlor in environmental waters
S-Òì±û¼×²Ý°·£¨S-MET£©ÊÇÎÒ¹úÉú²úºÍʹÓÃÁ¿×î´óµÄ³ý²Ý¼ÁÖ®Ò»£¬£¬£¬Æä»¯Ñ§ÌØÕ÷µ¼ÖÂÆä¿ÉÔÚÍÁÈÀÖг¤ÆÚ±£´æÒÔ¼°ÈÝÒ×ͨ¹ýÁÜÈܺͳÁ½µÎÛȾµØ±íË®ºÍµØÏÂË®£¬£¬£¬×îÖÕÓ°ÏìÖ²ÎïÉú³¤ºÍͨ¹ýʳÎïÁ´Î£º¦ÈËÀàÉúÃü¿µ½¡¡£¡£¡£¡£¼øÓÚÏÖÓмì²âÒªÁìµÄ¾ÖÏÞÐԺͶԸßЧÆÊÎö¼¼ÊõµÄÆÈÇÐÐèÇ󣬣¬£¬¸ÃÑо¿ÒÔS-metolachlorΪ¹¤¾ß£¬£¬£¬Ê¹Óò¸È鶯Îï±í´ïϵͳÌìÉúÏà¹ØÖØ×鿹Ìå¡£¡£¡£¡£ÔÚÀֳɱí´ï¿¹ÌåµÄ»ù´¡ÉÏ£¬£¬£¬Àֳɽ¨ÉèÁË»ùÓÚÕâЩ¿¹ÌåµÄÃâÒ߯ÊÎöÒªÁ죬£¬£¬ÓÃÓÚ¼à²âÇéÐÎË®ÑùÖеÄS-Òì±û¼×²Ý°·²ÐÁô¡£¡£¡£¡£icELISAЧ¹ûÏÔʾ£¬£¬£¬ÖØ×鿹ÌåµÄѸËٶȺÍÌØÒìÐÔÓëÇ×±¾µ¥¿¹ÏàËÆ£¬£¬£¬¿É¼á³ÖÔÓеÄÉúÎïѧ»îÐÔ£¬£¬£¬¹ØÓڽˮ¡¢Å©ÌïË®ºÍ×ÔÀ´Ë®ÖеÄS-MET£¬£¬£¬¾ßÓÐÓÅÒìµÄ׼ȷÐÔºÍÖØ¸´ÐÔ¡£¡£¡£¡£

ͼ½âÕªÒª
Dumbbell probe initiated multi-rolling circle amplification assisted CRISPR/Cas12a for highly sensitive detection of clinical microRNA
ϸСRNA£¨miRNA£©ÊÇÒ»ÀàСµÄ·Ç±àÂëRNA·Ö×Ó£¬£¬£¬Í¨¹ýÓëÌØ¶¨°Ð»ùÒòµÄÐÅʹRNA£¨mRNA£©Ï໥×÷ÓÃÀ´µ÷¿Ø»ùÒò±í´ï¡£¡£¡£¡£miRNAÔÚ¶àÖÖ¼²²¡µÄ±¬·¢¡¢Éú³¤Àú³ÌÖÐÊÎÑÝ×ÅÖ÷Òª½ÇÉ«£¬£¬£¬±»ÒÔΪÊǼ«¾ßDZÁ¦µÄ¼²²¡ÉúÎï±ê¼ÇÎï¡£¡£¡£¡£¸ÃÑо¿Ê¹ÓÃCRISPR/Cas12a¿ª·¢ÁËÒ»ÖÖΪDBmRCAµÄÐÂÐÍmiRNA¼ì²â¼¼Êõ¡£¡£¡£¡£¸Ã¼¼ÊõʹÓÃÎÞÅþÁ¬Ã¸µÄÑÆÁå̽ÕëºÍ¸ßѸËٶȵÄCRISPR/Cas12aÐźÅÊä³ö²ßÂÔ£¬£¬£¬ÊµÏÖÁËÔÚ30·ÖÖÓÄÚ¶ÔmiRNAµÄ¸ß¾«¶È¶¨Á¿ÆÊÎö¡£¡£¡£¡£Ñо¿ÍŶÓͨ¹ýÁÙ´²Ñù±¾ÑéÖ¤Á˸ü¼ÊõµÄÓÐÓÃÐÔ£¬£¬£¬·¢Ã÷miR-200aºÍmiR-126Ôڷΰ©×éÖ¯Öеıí´ïˮƽÏÔÖø½µµÍ£¬£¬£¬ÇҸü¼ÊõÓë¹Å°åÒªÁìЧ¹ûÒ»Ö¡£¡£¡£¡£DBmRCA¼¼Êõ¾ßÓÐʱ¼äЧÂʸߡ¢Ñ¸ËÙ¶ÈÇ¿ºÍ²Ù×÷Á÷³Ì¼ò»¯µÈÓŵ㣬£¬£¬ÎªÁÙ´²miRNAÆÊÎöÌṩÁËÒ»ÖÖ¿É¿¿µÄ¹¤¾ß£¬£¬£¬ÓÐÍûÖúÁ¦·Î°©µÄÔçÆÚÕï¶ÏºÍÖÎÁÆ¡£¡£¡£¡£

ͼ½âÕªÒª
ÍêÃÀÕæÈË